Genmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 73,000 shares, a growth of 30.1% from the March 31st total of 56,100 shares. Currently, 0.1% of the company's shares are short sold. Based on an average daily volume of 16,800 shares, the short-interest ratio is presently 4.3 days.
Genmab A/S Stock Performance
Shares of OTCMKTS:GNMSF traded up $14.99 during midday trading on Friday, reaching $220.09. The company had a trading volume of 6 shares, compared to its average volume of 3,022. The company has a fifty day simple moving average of $201.56 and a two-hundred day simple moving average of $208.42. The firm has a market cap of $14.54 billion, a price-to-earnings ratio of 12.56 and a beta of 1.10. Genmab A/S has a 1-year low of $170.00 and a 1-year high of $305.09.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share for the quarter, topping the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 36.30% and a return on equity of 19.75%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
